Donor Umbilical Cord Blood Transplant With or Without Ex-Vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes [clinicaltrials:NCT01690520]

Bio2RDF identifier

NCT01690520

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT01690520

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT01690520

anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]

160

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT01690520 arm group 9dfb050b6cdd89911f9aaf059006a2eb [clinicaltrials_resource:NCT01690520/arm-group/9dfb050b6cdd89911f9aaf059006a2eb]

NCT01690520 arm group f93a7dd26164242c719f9114725efe7c [clinicaltrials_resource:NCT01690520/arm-group/f93a7dd26164242c719f9114725efe7c]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

This randomized phase I ...... blood transplant alone.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Donor Umbilical Cord Blood Tra ...... , or Myelodysplastic Syndromes

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Time to engraftment defined as the first 3 consecutive days in which ANC >= 500 in both arms (standard myeloablative CBT with and without off-the-shelf expanded cord blood progenitors) Up to 2 years [clinicaltrials_resource:86dfdd2412ac169563e3e9eaaf08e5b7]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Time to engraftment defined as the first 3 consecutive days in which ANC >= 500 in both arms (standard myeloablative CBT with and without off-the-shelf expanded cord blood progenitors) Up to 2 years [clinicaltrials_resource:0a4d52a9a2c92548e662d48313dd726e]

Time to engraftment defined as the first 3 consecutive days in which ANC >= 500 in both arms (standard myeloablative CBT with and without off-the-shelf expanded cord blood progenitors) Up to 2 years [clinicaltrials_resource:47683a2e2e1b2460a0b0eceb7ded2d32]

Time to engraftment defined as the first 3 consecutive days in which ANC >= 500 in both arms (standard myeloablative CBT with and without off-the-shelf expanded cord blood progenitors) Up to 2 years [clinicaltrials_resource:51e47706e07ba79e4eb35156e7c4b2ff]

Time to engraftment defined as the first 3 consecutive days in which ANC >= 500 in both arms (standard myeloablative CBT with and without off-the-shelf expanded cord blood progenitors) Up to 2 years [clinicaltrials_resource:549e72304821fc46f0fc5736912cee90]

Time to engraftment defined as the first 3 consecutive days in which ANC >= 500 in both arms (standard myeloablative CBT with and without off-the-shelf expanded cord blood progenitors) Up to 2 years [clinicaltrials_resource:688c9c1615ca2f273e68576901074a47]

Time to engraftment defined as the first 3 consecutive days in which ANC >= 500 in both arms (standard myeloablative CBT with and without off-the-shelf expanded cord blood progenitors) Up to 2 years [clinicaltrials_resource:7b9d340fa49e7e800b2670817f5e16d9]

Time to engraftment defined as the first 3 consecutive days in which ANC >= 500 in both arms (standard myeloablative CBT with and without off-the-shelf expanded cord blood progenitors) Up to 2 years [clinicaltrials_resource:87f4d5e468993e9faa2bba9ee8d124b4]

Time to engraftment defined as the first 3 consecutive days in which ANC >= 500 in both arms (standard myeloablative CBT with and without off-the-shelf expanded cord blood progenitors) Up to 2 years [clinicaltrials_resource:9d99c7c6f2c7e8f48de386f69e8208e0]

Time to engraftment defined as the first 3 consecutive days in which ANC >= 500 in both arms (standard myeloablative CBT with and without off-the-shelf expanded cord blood progenitors) Up to 2 years [clinicaltrials_resource:9fb4546d655693f3c54c8fba53350736]

Time to engraftment defined as the first 3 consecutive days in which ANC >= 500 in both arms (standard myeloablative CBT with and without off-the-shelf expanded cord blood progenitors) Up to 2 years [clinicaltrials_resource:b494b21ed387d58cd4e85e6c5a984b74]

detailed description [clinicaltrials_vocabulary:detailed-description]

PRIMARY OBJECTIVES: ...... up periodically for 2 years.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT01690520 [clinicaltrials_resource:aba109030838b0cad1475ebb8a3bc2fc]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2012-09-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Double-Unit Umbilical Cord Blood Transplantation [clinicaltrials_resource:10786ed00064bd2ec601734a9e3a6692]

Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion [clinicaltrials_resource:714838d309d252d9913f79618dbd7e19]

Cyclosporine [clinicaltrials_resource:74f6b13487a273618a612202cc6fde3e]

Fludarabine Phosphate [clinicaltrials_resource:84c61d84515f8963db01f014d74b8379]

Mycophenolate Mofetil [clinicaltrials_resource:859726bd4c12dda931fa6fb83f32bf3d]

Cyclophosphamide [clinicaltrials_resource:897796ecd1ccbb9948874b92b409303f]

Total-Body Irradiation [clinicaltrials_resource:d003c2708f533e3fa03f04a992598002]

Laboratory Biomarker Analysis [clinicaltrials_resource:f647685cc96e0d62e7c222cab94a14f9]

Umbilical Cord Blood Transplantation [clinicaltrials_resource:faea3c91d80ad0af7bb3d10871b18ffd]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Vidarabine [clinicaltrials_resource:0b9503b52f4716847f6b86ffeb1f688e]

Mycophenolate mofetil [clinicaltrials_resource:31de209b7264303fdda3c8b57bf0b039]

Cyclophosphamide [clinicaltrials_resource:3ce44b0744f939109fd7f3f0a532c2d2]

Cyclosporins [clinicaltrials_resource:a78396bd0ab3d3f25852a0d4008cbdf4]

Cyclosporine [clinicaltrials_resource:d5ad0819e34429f7e4abc786a3f5366c]

Fludarabine [clinicaltrials_resource:dbdc12a37fe4f6695a2a1d9618cf73fe]

Mycophenolic Acid [clinicaltrials_resource:f75b029fbf569731a07aa713250d93da]

Fludarabine phosphate [clinicaltrials_resource:f95110c97018247ccfd75c6ec0f2f197]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Fred Hutchinson Cancer Research Center [clinicaltrials_resource:0413b67bb11aa7435c2cb6e1a4385dec]

location [clinicaltrials_vocabulary:location]

City of Hope Comprehensive Cancer Center [clinicaltrials_resource:c449d0db5ec34152e7fdce4d56316175]

nct id [clinicaltrials_vocabulary:nct-id]

NCT01690520

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

2

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Multi-center, Open-Label Rando ...... With Hematologic Malignancies

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

2.603e+3

http://www.w3.org/2001/XMLSchema#float

overall official [clinicaltrials_vocabulary:overall-official]

Colleen Delaney [clinicaltrials_resource:bf575693a6df88b7cbb1468af10137c5]

overall status [clinicaltrials_vocabulary:overall-status]

Recruiting [clinicaltrials_resource:5231dee7156b84b0d1854de1a18dd169]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:be4cea82cb21bbda79c939a4d720315b]

phase [clinicaltrials_vocabulary:phase]

Phase 2 [clinicaltrials_resource:56e0338b27a2d68f77402c88327b3f8d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2017-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

NCI-2012-01572

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

Fred Hutchinson Cancer Research Center [clinicaltrials_resource:0413b67bb11aa7435c2cb6e1a4385dec]

start date [clinicaltrials_vocabulary:start-date]

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT01690520 study design [clinicaltrials_resource:42a06a8cddcfb9655bf6116d3bdf92cb]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT01690520

verification date [clinicaltrials_vocabulary:verification-date]

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT01690520

http://www.w3.org/2001/XMLSchema#string

title

Donor Umbilical Cord Blood Tra ...... , or Myelodysplastic Syndromes

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Donor Umbilical Cord Blood Tra ...... s [clinicaltrials:NCT01690520]

@en